Month: January 2022
COVID Patient/Caregiver/Visitor Guidelines
Maryland Oncology Hematology Announces Carolyn Hendricks, MD, FASCO Has Been Named to the Board of The American Society of Clinical Oncology
The ASCO’s Board of Directors is comprised of oncology leaders who are elected to positions reflecting various specialties within the oncology field.
Bethesda, MD (January 2022) — Maryland Oncology Hematology (MOH), the largest independent oncology practice in Maryland and a member of The US Oncology Network, announced today that medical oncologist Carolyn Hendricks, MD, FASCO has been named to the Board of The American Society of Clinical Oncology. Dr. Hendricks was elected to the Designated Community Oncologist seat and will begin a four-year term starting in June 2022.
Dr. Hendricks is a medical oncologist specializing in breast cancer genetics, screening, and treatment at Maryland Oncology Hematology. She has served on a number of ASCO committees, including as chair of the ABIM-ASCO Breast Cancer Exam Subcommittee, chair-elect of the Practice Quality Improvement Steering Group, past chair of the Government Relations Committee, and a member of Clinical Practice Committee and the Quality Training Program Steering Group, among another volunteer service. Dr. Hendricks was honored as Advocate of the Year by the Association for Clinical Oncology in 2019.
Dr. Hendricks specializes in breast cancer and is an active member of a multidisciplinary team focused on breast cancer genetics, screening, and treatment. She provides leading-edge and comprehensive treatment at the local level. Praised for her involvement in clinical trials for breast cancer, she brings knowledge and support to community groups by providing education about breast cancer.
Her greatest accomplishments include her ASCO (American Society of Clinical Oncology) volunteer activities both nationally and internationally in the area of quality cancer care. She received the prestigious ASCO Fellowship Award in June 2018. Dr. Hendricks is also known for heightening breast cancer awareness and delivering quality breast cancer care throughout her career.
“We are thrilled to congratulate Dr. Hendricks on this incredible achievement,” said Joseph M. Haggerty, M.D, Practice President at Maryland Oncology Hematology. “With her focus on promising new advancements in breast cancer treatment and her commitment to providing education throughout the community, Dr. Hendricks is integral in delivering comprehensive and expert care to our breast patients.”
Dr. Hendricks is currently seeing patients at MOH’s Bethesda location. Immediate appointments are available for newly referred patients to provide a high level of support and prompt access to care. Please call 301.424.6231 to make an appointment.
About Maryland Oncology Hematology
Maryland Oncology Hematology (MOH) is the largest independent oncology practice in the state of Maryland, with more than 45 practicing clinicians devoted exclusively to providing comprehensive, compassionate, and high-quality cancer care. MOH specializes in medical, gynecologic, hematology, cancer genetic risk assessment, clinical trials and research, and patient ancillary programs. MOH believes it is beneficial to provide cancer therapies in a community setting, close to patients’ homes and support systems. The physicians are supported by a talented clinical team sensitive to the needs of cancer patients and their caregivers. For more information, visit MarylandOncology.com.
About US Oncology Network
Maryland Oncology Hematology is a practice in The US Oncology Network (The Network). This collaboration unites the practice with more than 1,380 independent physicians dedicated to delivering value-based, integrated care to patients — close to home. Through The Network, these independent doctors come together to form a community of shared expertise and resources dedicated to advancing local cancer care and to delivering better patient outcomes. The Network is supported by McKesson Corporation, whose coordinated resources and infrastructure allow doctors in The Network to focus on the health of their patients, while McKesson focuses on the health of their practices. MOH also participates in clinical trials through US Oncology Research, which has played a role in more than 100 FDA-approved cancer therapies.
To be distributed to local media:
Practice: Maryland Oncology Hematology
Contact: Mark Lamplugh